Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.69 |
| ▸ | PDE4A | P27815 | 19/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 19/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 19/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123232 | 0.85 | PDE4B (0.76) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6546406 | 0.85 | PDE4B (0.82) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6546049 | 0.85 | PDE4B (0.82) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6546052 | 0.85 | PDE4B (0.82) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL30295117 | 0.85 | PDE4B (0.70) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6635890 | 0.84 | PDE4B (0.81) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL433298 | 0.83 | PDE4B (0.68) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL29351482 | 0.83 | PDE4B (0.68) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6545916 | 0.83 | PDE4B (0.86) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6545912 | 0.83 | PDE4B (0.86) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2010513276-A | — | — | 2010-04-30 | — | — | JP | claimed |
| US-20100098641-A1 | Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction | GILEAD SCIENCES, INC. | 2010-04-22 | — | — | US | claimed |
| EP-2125841-A1 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF ANTI-INFLAMMATORY SIGNAL TRANSDUCTION MODULATORS (AISTM'S) AND BETA-AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION | Gilead Sciences, Inc. (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2008076265-A1 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF ANTI-INFLAMMATORY SIGNAL TRANSDUCTION MODULATORS (AISTM'S) AND β-AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION | GILEAD SCIENCES, INC. (US) | 2008-06-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098641-A1 | Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction | ADRB1, ADRB2, PDE11A | PDE4B 13/4885PDE4A 10/4885PDE4C 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.